Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. MDCX
MDCX logo

MDCX Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Medicus Pharma Ltd (MDCX) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
0.500
1 Day change
1.01%
52 Week Range
8.940
Analysis Updated At
2026/03/20
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.
Sign Up

Medicus Pharma Ltd (MDCX) is not a strong buy at the moment, given the lack of positive catalysts, weak financial performance, and bearish technical indicators. For a beginner investor with a long-term focus, this stock does not present a compelling opportunity right now.

Technical Analysis

The technical indicators are bearish. The MACD is below 0 and negatively contracting, indicating weak momentum. The RSI is at 28.48, which is neutral but close to oversold levels. Moving averages suggest a bearish trend (SMA_200 > SMA_20 > SMA_5). The stock is trading below its pivot level of 0.53, with key support at 0.395 and resistance at 0.665.

Positive Catalysts

  • NULL identified. There is no recent news or significant trading trends from hedge funds or insiders.

Neutral/Negative Catalysts

  • The stock has shown a consistent downward trend in price, with a pre-market change of -1.56% and post-market change of -2.00%. Financial performance is weak, with negative net income and EPS despite YoY improvements.

Financial Performance

In Q3 2025, revenue remained at 0 with no YoY growth. Net income improved YoY but remains negative at -20,935,753. EPS also improved YoY but is still negative at -1.12. Gross margin is 0, indicating no profitability.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating or price target changes available.

Wall Street analysts forecast MDCX stock price to rise
1 Analyst Rating
Wall Street analysts forecast MDCX stock price to rise
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.494
sliders
Low
12
Averages
12
High
12
Current: 0.494
sliders
Low
12
Averages
12
High
12
Brookline
Buy
upgrade
$12 -> $20
AI Analysis
2025-09-24
Reason
Brookline
Price Target
$12 -> $20
AI Analysis
2025-09-24
upgrade
Buy
Reason
Brookline raised the firm's price target on Medicus Pharma to $20 from $12 and keeps a Buy rating on the shares. The firm is updating its model following completion of aquisition of Antev Limited. Medicus acquired 98.6% of Antev for $75M, which includes $2.97M in cash and 1,603,164 common shares of Medicus, plus $65M in contingent payments tied to potential future Teverelix Phase 2 trial data and New Drug Application approvals. Brookline is including the potential of Teverelix in Acute Urinary Retention in its model, but does not include the potential for Teverelix in prostate cancer in its model and expects to add it to the model following Phase 2 data.
D. Boral Capital
Jason Kolbert
Buy
maintain
$14 -> $27
2025-05-12
Reason
D. Boral Capital
Jason Kolbert
Price Target
$14 -> $27
2025-05-12
maintain
Buy
Reason
D. Boral Capital analyst Jason Kolbert raised the firm's price target on Medicus Pharma to $27 from $14 and keeps a Buy rating on the shares after the company signed a binding letter of intent to acquire Antev. This acquisition adds "significant strategic value" by bringing in Teverelix, a next-generation GnRH antagonist with strong clinical rationale and late-stage readiness, the analyst tells investors in a research note. The firm says Teverelix addresses two large, underserved markets - acute urinary retention recurrence prevention and advanced prostate cancer in patients with high cardiovascular risk. D. Boral views the transaction as a "savvy, de-risked pipeline expansion that materially enhances Medicus' near-commercial portfolio and positions the company for accelerated value creation."
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for MDCX
Unlock Now

People Also Watch